CoChat

Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)

Open access
Bachy, Emmanuel, Camus, Vincent, Thieblemont, Catherine, Sibon, David, Casasnovas, René-Olivier, Ysebaert, Loïc, Damaj, Gandhi, Guidez, Stéphanie, Pica, Gian Matteo, Kim, Won Seog, Lim, Soon Thye, André, Marc, García-Sancho, Alejandro Martín, Penarrubia, Maria Jesus, Staber, Philipp B., Trotman, Judith, Hüttmann, Andreas, Stefoni, Vittorio, Re, Alessandro, Gaulard, Philippe, Delfau-Larue, Marie-Helene, de Leval, Laurence, Meignan, Michel, Li, Ju, Morschhauser, Franck, Delarue, Richard · 2022 · Journal of Clinical Oncology
Cited by 197

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

PURPOSE: Romidepsin, a histone deacetylase inhibitor, has demonstrated activity in relapsed or refractory peripheral T-cell lymphoma (PTCL) as a single agent. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy is widely used as first-line treatment of PTCL; however, it has limited efficacy. Results from a phase Ib and II study showed the feasibility of combining romidepsin with CHOP (Ro-CHOP). METHODS: This study is a randomized phase III study of Ro-CHOP versus CHOP in adult patients with previously untreated PTCL. All patients received CHOP in 3-week cycles for six cycles. Romidepsin, 12 mg/m 2, was administered intravenously over a 4-hour period on days 1 and 8 of each 3-week cycle for six cycles. The primary end point was progression-free survival (PFS) according to International Working Group 1999 criteria. RESULTS: Between January 2013 and December 2017, 421 patients were enrolled (Ro-CHOP, n = 211; CHOP, n = 210). The median PFS for Ro-CHOP versus CHOP was 12.0 months (95% CI, 9.0 to 25.8) versus 10.2 months (95% CI, 7.4 to 13.2) with a hazard ratio of 0.81 ( P = .096). In the Ro-CHOP versus CHOP arms, the median overall survival was 51.8 versus 42.9 months and the objective response rate was 63% versus 60% with complete response plus unconfirmed complete response rates of 41% versus 37% ( P > .1 in all comparisons), respectively. Grade 3 or 4 treatment-emergent adverse events occurring in ≥ 30% of patients in the Ro-CHOP arm included thrombocytopenia (50% v 10% in the Ro-CHOP v CHOP arms, respectively), neutropenia (49% v 33%), anemia (47% v 17%), and leukopenia (32% v 20%). CONCLUSION: The addition of romidepsin to CHOP did not improve PFS, response rates, nor overall survival and increased the frequency for grade ≥ 3 treatment-emergent adverse events. Ro-CHOP does not represent a significant advance in the standard of care for patients with previously untreated PTCL.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.21.01815

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 197

Metadata

Authors
Bachy, E., Camus, V., Thieblemont, C., Sibon, D., Casasnovas, R.-O., Ysebaert, L., Damaj, G., Guidez, S., Pica, G. M., Kim, W. S., Lim, S. T., André, M., García-Sancho, A. M., Penarrubia, M. J., Staber, P. B., Trotman, J., Hüttmann, A., Stefoni, V., Re, A., Gaulard, P., Delfau-Larue, M.-H., de Leval, L., Meignan, M., Li, J., Morschhauser, F., & Delarue, R.
Venue
Journal of Clinical Oncology
Published
2022-01-20
Volume
40
Issue
3
Pages
242-251
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W3217609143
Cited by
197
References
13
FWCI
19.63
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA). https://app.cochat.ai/papers/10.1200/jco.21.01815
The paper
Bachy, E., Camus, V., Thieblemont, C., Sibon, D., Casasnovas, R.-O., Ysebaert, L., Damaj, G., Guidez, S., Pica, G. M., Kim, W. S., Lim, S. T., André, M., García-Sancho, A. M., Penarrubia, M. J., Staber, P. B., Trotman, J., Hüttmann, A., Stefoni, V., Re, A., . . . Delarue, R. (2022). Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA). Journal of Clinical Oncology. https://doi.org/10.1200/jco.21.01815

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.